



# Fresubin Hepa

Ready to use in 500 mL EasyBag



## Nutritional Information

Average content	100 mL	
<b>Energy value</b>	kJ (= kcal)	550 (130)
<b>Fat (33% Energy)</b>	g	4.7
of which saturated fatty acids	g	2.0
of which medium chain triglycerides	g	1.7
of which monounsaturated fatty acids	g	1.4
of which polyunsaturated fatty acids	g	1.3
<b>Carbohydrate (53.5% Energy)</b>	g	17.4
of which sugars	g	0.7
of which lactose	g	≤ 0.01
<b>Fibre (1.5% Energy)</b>	g	1.0
<b>Protein (12% Energy)</b>	g	4.0
of which branched chain amino acids 44%	g	1.93
<b>Salt (Na x 2.5)</b>	g	0.19
<b>Water</b>	mL	78
<b>Gluten</b>	ppm	≤ 20
<b>Lactose</b>	g	≤ 0.01
<b>Osmolarity</b>	mosmol/l	330
<b>Osmolality</b>	mosmol/kg H <sub>2</sub> O	420
<b>Minerals and trace elements</b>		
Sodium	mg	75
Chloride	mg	71.5
Potassium	mg	120
Calcium	mg	80
Phosphorus	mg	53
Magnesium	mg	27
Iron	mg	1.33
Zinc	mg	1.2
Copper	µg	130
Iodine	µg	13.3
Selenium	µg	6.67
Manganese	mg	0.27
Chromium	µg	6.67
Molybdenum	µg	10
Fluoride	mg	0.13
<b>Vitamins and other* substances</b>		
Vitamin A	µg RE <sup>o</sup>	92
of which β-Carotene	µg RE <sup>o</sup>	22
Vitamin D <sub>3</sub>	µg	1.0
Vitamin E	mg α-TE <sup>oo</sup>	1.33
Vitamin K <sub>1</sub>	µg	6.67
Vitamin C	mg	6.67
Thiamin (vitamin B <sub>1</sub> )	mg	0.13
Riboflavin (vitamin B <sub>2</sub> )	mg	0.17
Vitamin B <sub>6</sub>	mg	0.16
Niacin	mg/mg NE <sup>ooo</sup>	1.6/2.3
Folic Acid	µg	27
Vitamin B <sub>12</sub>	µg	0.27
Pantothenic Acid	mg	0.47
Biotin	µg	5.0
Choline*	mg	28

\*retinol equivalents (RE), <sup>oo</sup>alpha-tocopherol equivalents (α-TE), <sup>ooo</sup>niacin equivalents (NE)

## Prescribing Information

### Food for special medical purposes:

Nutritionally complete, high-caloric (1.3 kcal/mL) tube feed with fibre; increased in branched chain amino acids and with medium chain triglycerides (MCT). Low in lactose and gluten. For the dietary management of patients with or at risk of disease-related malnutrition in particular with acute and chronic liver failure.

### Dosage:

To be determined by a health care professional according to patients' needs. Recommendation for complete nutrition ≥ 1.500 mL (1950 kcal) / day.

### Important notes:

To be used under medical supervision. Monitor feeding rate. Suitable as sole source of nutrition. Not suitable for infants < 1 year. Use with caution in children < 6 years. Not suitable for patients with galactosaemia. Ensure adequate fluid intake. **Not for parenteral (I.V.) use.**

### Instructions for use:

Recommended tube size: ≥ CH 5 for pump assisted feeding, ≥ CH 12 for gravity feeding. Store at room temperature. Once opened, use within 24 hours. Shake well before use! Do not use if bag is damaged or swollen or content is coagulated. Do not mix with drugs.

### Contraindications:

Not suitable whenever enteral nutrition is not permitted such as in acute gastrointestinal bleeding, ileus and shock. Use with caution in severe organ failure with impaired metabolism and severe forms of malabsorption. Not suitable for patients with congenital inability to metabolise nutrients contained in Fresubin Hepa.

## Ingredients

Water, maltodextrin, vegetable oils (rapeseed oil, soya oil), medium chain triglycerides (MCT), soy protein, soy polysaccharides, milk protein, l-leucine, l-valine, l-arginine hydrochloride, potassium citrate, l-isoleucine, calcium phosphate, sodium citrate, magnesium citrate, choline chloride, vit. C, acidity regulator (E 330), magnesium oxide, calcium carbonate, thickener (E 407), iron sulphate, zinc sulphate, niacin, vit. E, manganese chloride, pantothenic acid, sodium fluoride, vit. B<sub>2</sub>, vit. B<sub>6</sub>, copper sulphate, vit. B<sub>1</sub>, vit. A, β-carotene, folic acid, chromium chloride, sodium molybdate, potassium iodide, sodium selenite, biotin, vit. K<sub>1</sub>, vit. D<sub>3</sub>, vit. B<sub>12</sub>.

**Allergen Information: This product contains milk, soy and fish oil.**

## References

- Plauth M, Cabre E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006; 25(2): 285-294.
- Amodio P, Bemeur C, Butterworth R, et al. The Nutritional Management of Hepatic Encephalopathy in Patients With Cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013; 58(1): 325-336.
- Glud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Library. 2007. CD001939
- Kawaguchi T, Taniguchi E, Sata M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutrition in Clinical Practice. 2013; 28(5): 580-588.
- Ginés P, Angeli P, Lenz K, et al. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53(3): 397-417.
- Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6): 2087-2107.
- Babayán VK. Medium chain triglycerides and structured lipids. Lipids. 1987; 22(6): 417-420.
- Lochs H, Allison SP, Meier R, et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: terminology, definitions and general topics. Clin Nutr. 2006; 25(2): 180-186.



**FRESENIUS  
KABI**

caring for life

Fresenius Kabi Australia Pty Limited  
Level 2, 2 Woodland Way,  
Mount Kuring-gai NSW 2080  
Phone 1300 732 001  
Fax 1300 304 384  
www.fresenius-kabi.com.au

Fresenius Kabi New Zealand Limited  
60 Pavilion Drive, Māngere  
Auckland 2022 New Zealand  
Phone 0800 144 892  
Fax +64 9925 2721  
PM2019.553V2 Pub: September 2020